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Abstract
Background:  Little is known about the transfer of care process from pediatric to adult
rheumatology for patients with chronic rheumatic disease. The purpose of this study is to examine
changes in disease status, treatment and health care utilization among adolescents transferring to
adult care at the University of California San Francisco (UCSF).
Methods: We identified 31 eligible subjects who transferred from pediatric to adult rheumatology
care at UCSF between 1995–2005. Subject demographics, disease characteristics, disease activity
and health care utilization were compared between the year prior to and the year following
transfer of care.
Results: The mean age at the last pediatric rheumatology visit was 19.5 years (17.4–22.0). Subject
diagnoses included systemic lupus erythematosus (52%), mixed connective tissue disease (16%),
juvenile idiopathic arthritis (16%), antiphospholipid antibody syndrome (13%) and vasculitis (3%).
Nearly 30% of subjects were hospitalized for disease treatment or management of flares in the year
prior to transfer, and 58% had active disease at the time of transfer. In the post-transfer period,
almost 30% of subjects had an increase in disease activity. One patient died in the post-transfer
period. The median transfer time between the last pediatric and first adult rheumatology visit was
7.1 months (range 0.7–33.6 months). Missed appointments were common in the both the pre and
post transfer period.
Conclusion:  A significant percentage of patients who transfer from pediatric to adult
rheumatology care at our center are likely to have active disease at the time of transfer, and disease
flares are common during the transfer period. These findings highlight the importance of a seamless
transfer of care between rheumatology providers.
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Background
It is estimated that 8–10% of adolescents in the United
States have a chronic health condition that will require
ongoing care into adulthood. This population is expected
to grow as survival for children with chronic illness
improves [1,2]. As a group, the pediatric rheumatic dis-
eases, including juvenile idiopathic arthritis (JIA), sys-
temic lupus erythematosus (SLE) and vasculitis, are
among the most common chronic diseases of childhood.
Juvenile idiopathic arthritis, the most common of these
conditions, affects approximately 1 per 1000 children in
the United States [3,4]. Although JIA remits in some
patients, several recent studies have demonstrated that
30–60% percent of JIA patients continue to have active
disease into adulthood [5-8]. Packham and Hall exam-
ined the clinical and functional outcomes of 246 adult
patients with childhood-onset JIA and found that 43% of
subjects continued to have clinically active disease after an
average disease duration of 28 years. Additionally,
approximately 40% of adult subjects had 'severe disabil-
ity' as a result of JIA [9,10].
Remission in childhood SLE is even less common than in
JIA [11]. End-organ damage, including chronic renal dis-
ease and neurologic sequelae, is more common in child-
hood than adult-onset SLE and can lead to significant
impairment in functional outcomes and health related
quality of life [12,13]. Despite substantial improvement
in short-term survival during the past several decades, a
significant percentage of SLE patients continue to die pre-
maturely. In a 2004 study, the ten-year survival for child-
hood SLE patients was only 86%, and a recent study by
Tucker et al suggests that patients with adolescent-onset
SLE have a mortality rate twice that of their adult counter-
parts [14,15].
As a result of the chronic nature of the rheumatic diseases,
most pediatric rheumatology patients require transfer of
care from pediatric to adult rheumatology providers.
Studies examining the transfer of care process in pediatric
rheumatology and other chronic childhood diseases sug-
gest that significant barriers exist with this process. Using
data from the National Survey of Children with Special
Health Care Needs, Scal et al reported on the proportion
of adolescents with arthritis who received transition coun-
seling and found that only half of young people had had
a discussion with their provider about how their health
needs will change into adulthood. Other transition issues
that were addressed less commonly included acquiring
insurance (22.5%) and transfer of care to an adult pro-
vider (19%) [16]. In a Canadian study describing the prev-
alence of successful transfer of care among patients with
congenital heart disease, only 47% of subjects successfully
transferred care, which was defined as attendance at an
adult cardiology visit after discharge from pediatric cardi-
ology care [17]. Potential barriers to successful transfer of
care include factors attributable to the patient (lack of
adherence to treatment and follow-up recommenda-
tions), the physician (lack of familiarity with or time to
coordinate the transition process, inadequate communi-
cation between old and new providers), and the health
care system (lack of insurance, limited access to care) [18-
21].
In the literature, experts have drawn a distinction between
the terms "transfer" and "transition" of care. "Transfer of
care" is defined as the point at which a new provider
assumes the medical care of a patient, while "transition of
care" is defined as an "age and developmentally appropri-
ate process, addressing the medical, psychosocial and
educational/vocational aspects of care" [22]. Limited
studies suggest that the transfer of care is more likely to be
successful if a formal transition program is in place to pre-
pare the patient and to facilitate the change in care provid-
ers [23,24]. In addition, there are several recent reviews
which emphasize the importance of a transition program
for pediatric rheumatology patients [25-30].
In order to understand the transfer of care process for
young adults with chronic illness, we examined the demo-
graphic characteristics, disease outcomes and characteris-
tics of care of a group of young adult patients who
transferred care from the pediatric to adult rheumatology
clinics at the University of California San Francisco
(UCSF). By studying the change of care process within a
single institution, we aimed to identify obstacles to care
transfer, which could inform the development of a formal
program for transitioning pediatric rheumatology
patients to adult care at our institution.
Methods
Research Design
We conducted a retrospective cohort study of patients
who transferred care from the pediatric to adult rheuma-
tology clinics at UCSF between 1995 and 2005.
Clinical Practice
During the time period of this study, there was no formal
transition program in place in the Pediatric Rheumatol-
ogy clinic at UCSF. The majority of the patients in the
UCSF pediatric rheumatology clinic were transferred to
adult care between the ages of 18 and 21. The timing of
transfer was largely determined by insurance rules which
determine the age of transition from pediatric to adult
subspecialty care. (ex. California Children's Services man-
dates transition of care at age 21, regardless of disease
activity or availability of an adult provider).
Study Population
Eligible study subjects were identified by searching the
adult rheumatology clinic database to find patients with a
current age less than or equal to 30 years old who had atPediatric Rheumatology 2009, 7:13 http://www.ped-rheum.com/content/7/1/13
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least one scheduled adult rheumatology clinic visit
between 1995 and 2005. Eligible subjects were then cross
referenced with the pediatric rheumatology database to
determine the subset of patients who had also previously
been seen in the pediatric rheumatology clinic at UCSF.
Of the 51 subjects initially identified, 15 were excluded
because of unavailable records, and five were excluded
because they saw a non-UCSF adult rheumatology pro-
vider after leaving pediatric rheumatology and before re-
establishing care at UCSF. The subjects who were not
included in the analysis because of the lack of available
records did not differ from the study population with
regard to diagnosis, age, sex or ethnicity. Thirty-one sub-
jects were included in the final analysis.
Definition of Transfer Periods
In order to compare outcomes before and after the trans-
fer of care, two transfer periods were defined based on the
date of the last pediatric rheumatology visit and the first
adult rheumatology visit. The "pre-transfer period" was
defined as one year +/- two months before the last pediat-
ric visit and the "post-transfer period" was defined as one
year +/- two months after the first adult rheumatology
visit. We estimated that abstracting data from these time
periods would allow us to measure changes in clinically
relevant outcomes before and after the transfer of care.
Measures
Relevant demographic information and clinical outcomes
from the pre and post-transfer period were abstracted
from the UCSF pediatric and adult rheumatology medical
records for each subject (S.P.).
Demographic Characteristics
Information regarding various demographic characteris-
tics was collected including age, gender, self-declared race/
ethnicity, education and insurance status. Highest educa-
tional level achieved was reported in four categories: 1)
high school 2) community college/vocational school 3)
four year college and 4) graduate school. Insurance was
categorized as public (California Children's Services or
MediCal) or private (health maintenance organization
(HMO) or preferred provider organization (PPO)). The
distance traveled for pediatric rheumatology visits was cal-
culated using Mapquest, an internet-based travel tool that
provides a reasonable travel route and the mileage
between the subject's home zip code and UCSF.
Clinical Characteristics
Subject diagnosis was classified in five categories: 1) sys-
temic lupus erythematosus 2) juvenile idiopathic arthritis
(JIA) 3) mixed connective tissue disease (MCTD), 4)
antiphospholipid syndrome (APLS) and 5) vasculitis,
using the clinical diagnosis in the medical record. For the
purpose of our analysis, APLS and vasculitis were com-
bined and analyzed as a single diagnostic category.
The Systemic Lupus Erythematosus Disease Activity Index
(SLEDAI), a well validated composite measure of disease
activity in SLE, was used to measure disease activity for all
SLE subjects. In our clinical experience, a SLEDAI score of
1 or 2 indicates mild disease, while a SLEDAI score of = 3
indicates moderate disease. For non-SLE subjects, a global
physician assessment of disease activity was determined
by reviewing the clinical reports in the medical record
(S.P.) and the disease activity was classified as "none",
"mild/moderate" or "severe."
A complete medication list was obtained for each subject.
As a measure of disease activity, the maximum prednisone
dose was compared for the last pediatric and adult rheu-
matology visits.
The number of hospitalizations and the reasons for hospi-
talization (ex. disease flare versus scheduled in-patient
treatment) were determined. The number of pregnancies,
abortions and deaths in the cohort was also collected.
Appointments
The "transfer time" was defined as the time between the
date of the last pediatric rheumatology visit and the date
of the first appearance at an adult rheumatology visit. The
number of missed pediatric and adult rheumatology
appointments in the pre and post-transfer periods were
also collected.
Statistical Analysis
Baseline demographic and disease characteristics were
expressed using means, standard deviations (SD) and pro-
portions. We compared the difference in disease charac-
teristics pre and post transition using statistical tests (rank
sum, t-test, chi squared) as appropriate. For skewed data,
non-parametric tests of comparison (Wilcoxon sign rank,
Fisher Exact test) were used. P-values of < 0.05 were con-
sidered statistically significant.
All statistical analyses were performed using STATA soft-
ware, version 9.0 (StataCorp, College Station, TX). The
study protocol was approved by the UCSF Committee on
Human Research.
Results
Patient Characteristics
The demographic and socioeconomic characteristics of
the cohort are summarized in Table 1. The subject mean
age at the last pediatric rheumatology visit was 19.5 years
(17.4–22.0), and 74% of the cohort was female. Of the 31
subjects, approximately half had SLE (52%). Additional
diagnoses included JIA (16%), MCTD (16%), APLS (13%)
and vasculitis (3%) All of the subjects had graduated fromPediatric Rheumatology 2009, 7:13 http://www.ped-rheum.com/content/7/1/13
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high school, and 75% of the cohort continued schooling
beyond high school. Educational attainment did not vary
by underlying diagnosis, disease activity, or insurance sta-
tus. The distance traveled to UCSF during the pre-transfer
period ranged from 3 to 292 miles (median 20 miles).
Outcomes
Disease Activity
Change in disease activity pre and post-transfer was exam-
ined utilizing the SLEDAI score for subjects with SLE and
the global physician assessment for non-SLE subjects. At
the time of transfer, only one subject with SLE had quies-
cent disease (SLEDAI score = 0). Six of 16 (37%) SLE sub-
jects had a SLEDAI score of 1–2, and 9 of 16 (56%) had a
SLEDAI score = 3. In the post-transfer period, 5 subjects
(31%) had experienced no change in SLEDAI score, 4
(25%) had a decrease and 7 (44%) had an increase in
SLEDAI scores. There was no significant difference in the
median SLEDAI scores pre and post transfer (4 (range 0–
16) vs 4 (range 0–20), p = 0.3). Among non-SLE patients,
3/15 (20%) had active disease at the time of transfer; 2/15
(13%) subjects had an increase in the global physician rat-
ing of disease activity and the remaining 87% had no
change in disease activity in the post-transfer assessment.
These findings are summarized in Figure 1.
Hospitalizations
There were more hospitalizations in the year prior to
transfer than the year post-transfer (32 hospitalizations
among nine subjects, versus six hospitalizations among
three subjects, p = 0.017). This increased rate of hospital-
izations was largely due to scheduled hospitalizations for
IV cyclophosphamide administration, which were more
common in the pre-transfer period (21 vs 2, p = 0.03). No
differences in flare-associated hospitalizations were noted
between the two time periods. Hospitalizations in the pre-
and post-transfer period are presented in Table 2.
Glucocorticoid Use
Prednisone use was common in both the pre-transfer
(61%) and post-transfer (58%) periods. The mean pred-
nisone dose was higher in the pre-transfer period than the
post-transfer period (5 vs 2 mg/day, p = 0.04). Three
patients received intravenous methylprednisolone during
the pre-transfer period, versus four in the post-transfer
period.
Other Medications
In the pre-transfer period, 26/31 (84%) subjects were on
at least one medication for treatment of their rheumatic
disease including hydroxychloroquine (61%), cyclophos-
phamide (13%), methotrexate (13%), azathioprine
(10%), mycophenolate mofetil (13%), cyclosporine
(3%), and anti-tumor necrosis factor alpha agents (13%).
There were no differences in the frequency of use of these
medications between the pre-transfer and the post-trans-
fer periods.
Pregnancies and Abortions
In the pre-transfer period 3 of 23 female subjects became
pregnant; all three pregnancies were electively terminated.
In the post-transfer period there was one pregnancy which
was electively terminated.
Death
During the post-transfer period there was one death. The
patient was a 19 year old young woman with SLE who
transferred care when she was 18 years old because of a
change in her insurance coverage. The patient had active
SLE (SLEDAI score = 4) at the time of transfer, and her SLE
remained poorly controlled during the transfer period. It
is noted that the patient had 3 missed appointments in
Table 1: Subject demographics and disease characteristics.
Cohort
(n = 31)
Age, mean (range), y* 19.5 (17.4–22)
Diagnosis, No. (%)
Systemic Lupus Erythematosus 16 (51.7)
Mixed Connective Tissue Disease 5 (16.1)
APLS/Vasculitis 5 (16.1)
Juvenile Idiopathic Arthritis/Spondyloarthropathy 5 (16.1)
Gender, No. (%)
Female 23 (74)
Ethnicity, No. (%)
Caucasian 10 (32.2)
Asian 7 (22.6)
Hispanic 12 (38.7)
African American 2 (6.5)
Highest Level of Education, No. (%)
High school 7 (22.6)
Community College/Vocational 13 (42)
Four year college 9 (29)
Graduate school 2 (6.2)
*Age at last pediatric rheumatology visit
APLS = antiphospholipid antibody syndromePediatric Rheumatology 2009, 7:13 http://www.ped-rheum.com/content/7/1/13
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the adult rheumatology clinic in the post-transfer period.
The patient died from complications of SLE including dif-
fuse mesenteric vasculitis resulting in gastrointestinal
hemorrhage and sepsis.
Insurance
As summarized in Table 3, there was a significant change
in insurance status pre and post transfer. In the pre-trans-
fer period 75% of subjects had public insurance. In con-
trast, subjects were more likely to have private insurance
(55% vs 45% p = 0.037) in the post-transfer period. There
was no association between insurance status and educa-
tional achievement, transfer time or distance traveled to
UCSF for appointments.
Transfer time and missed clinic appointments
The median transfer time was 7.1 months (0.7 to 33).
Nine of 31 subjects (29%) subjects missed their first
scheduled adult rheumatology visit. No specific predictors
of increased transfer time, such as distance traveled or
insurance status, were identified. The number of subjects
who missed scheduled appointments was high in both
the pre and post transfer periods. In both time periods 10/
31 (32%) subjects had at least one missed appointment.
The rates of missed appointments in the pre and post
transfer periods were 15% and 21% respectively.
Discussion
As the population of children with chronic illness
expands, it is essential to understand how processes of
care, such as the transfer of medical care from one pro-
vider to another, affect the short and long-term outcomes
of our patients. The primary goal of this study was to
describe a population of pediatric rheumatology patients
during the time of transfer of care, and to determine if
there was a significant change in disease outcomes, such
as disease activity, during this critical time period. In addi-
tion, we hoped to improve our understanding of the
health care needs of young adults with chronic rheumatic
disease.
In the population of patients that we examined, the
majority (58%) of subjects had active disease at the time
of transfer. In addition, most were taking at least one med-
ication to treat their rheumatic disease, and over half were
Differences in disease activity between the Pre and Post  Transfer Period (n = 31) Figure 1
Differences in disease activity between the Pre and 
Post Transfer Period (n = 31).
Table 2: Changes in disease activity, hospitalizations and steroid dosing pre and post transfer.
Disease Activity Pre-Transfer Post-Transfer P value
Median (range) SLEDAI score* 4 (0–16) 4 (0–20) 0.3
Disease activity**
None 12 (80) 10 (67)
Mild/moderate 2 (13) 4 (27) 0.16
Severe 1 (7) 1 (7)
Number of Hospitalizations*
Total 32 6 0.017
Scheduled 21 2 0.03
Flare associated 8 4 0.26
Steroid Dosing
Median prednisone dose at last visit, mg (range) 5 (0–40) 2 (0–20) 0.004
Median peak prednisone dose, mg (range) 10 (0–60) 5 (0–60) 0.059
IV methylprednisolone, No (%) 3 (10) 4 (13) 0.99
* Systemic Lupus Erythematosus (n = 16)
**MCTD, APLS, Vasculitis, Spondylarthropathy (n = 15)
IV = IntravenousPediatric Rheumatology 2009, 7:13 http://www.ped-rheum.com/content/7/1/13
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hospitalized in the year prior to their transfer of care. Sim-
ilar findings were seen in a study of a British cohort of
adolescents with JIA, in which almost 80% of 17 year olds
had active disease prior to transfer from pediatric to adult
rheumatology, and almost two-thirds were on a DMARD
[31]. These findings highlight the importance of creating
a transition system which provides seamless transfer of
care between providers in order to meet the needs of these
medically complicated patients.
Because of the difficulties that can arise in the transfer of
care process, we hypothesized that there would be an
increase in disease activity around the time of transfer.
Although it is likely that our analysis was underpowered
to demonstrate a statistically significant difference in
median SLEDAI/global assessment scores, it is notable
that 29% of subjects experienced a worsening of disease
activity during the post-transfer follow-up time period.
This increase in disease activity may be a result of the nat-
ural history of the disease process, but it may also reflect
poor outcomes related to the transfer process. The pediat-
ric solid organ transplant literature suggests that the tran-
sition from late adolescence to young adulthood is one of
the most vulnerable periods for rejection and graft loss,
due to a variety of factors, including medication non-
adherence [32]. Regardless of the cause, the high rate of
disease flare in the post-transfer period emphasizes the
need for a comprehensive and dependable process for
these patients during this critical period.
Despite evidence of high disease activity, we were sur-
prised that the average transfer time between the last pedi-
atric rheumatology and first adult rheumatology visit,
within the same institution, was over seven months. The
number of missed appointments, which is likely a proxy
for patient compliance, was high in both the pre and post-
transfer periods, and may have contributed to the delay
between the last pediatric and first adult visit. Given the
complex medical needs of this population, any future
transition program at our institution will address the
obstacles that lead to delays to the first adult rheumatol-
ogy appointment.
With regard to insurance, a significant percentage of sub-
jects in our study transferred from public to private insur-
ance, and all subjects had obtained insurance coverage in
the post-transfer period. A recent study by Lotstein, et al
highlighted the difficulties with access to care for youth
with special health care needs living near Los Angeles, Cal-
ifornia [33]. This study demonstrated that among a popu-
lation of young adults with chronic disease, aged 21–24
years, 27% were without health care following discontin-
uation of their public insurance at the age of 21, and 39%
had delays in necessary care as a result of lapses in insur-
ance coverage. Given this data, it is likely that health out-
comes could be worse for uninsured patients with chronic
rheumatic disease.
Although the studies describing the clinical outcomes for
pediatric rheumatology patients after transfer of care are
limited, a small number of studies have examined the
short term outcomes of patients who have transferred care
in other health care systems or other disciplines. A recent
study from France by Dugueperoux et al, examined the
clinical changes of young adults with cystic fibrosis (CF)
during transition from a pediatric to adult CF center [34].
In this population, disease activity remained clinically sta-
ble over the transition period. In the discussion, the
authors note that given the flexibility in the timing of
transfer, all of the patients transferred care at a time when
they had stable disease. In the United States, timing of
transfer of care is often determined by insurance age lim-
its, and not based on the patient's optimal clinical status.
We observed some important outcomes related to transfer
of care and identified interesting trends which deserve fur-
ther exploration in future prospective studies. However,
there are several important limitations that need to be
considered. Although few studies have described the out-
comes of pediatric rheumatology patients after their trans-
fer of care, the sample size for our study was small, thereby
limiting the power for some of our analyses. The retro-
spective nature of this study limited the ability to assess
certain factors which could affect the transfer of care proc-
ess including self-management abilities, developmental
maturity, medication adherence and vocational and edu-
cational attainment; all essential issues which would be
addressed in a comprehensive transition program. In
addition, as a result of the study design, disease activity
was assessed through chart evaluations, and not through
direct patient examination. Because of record availability,
this study only examines the outcomes of subjects trans-
ferred within our institution, which limits generalizability
to other settings. In our experience, the location of adult
rheumatology follow-up is determined by multiple fac-
tors including the complexity of the patients' medical con-
dition, post-transfer insurance status and the availability
of adult rheumatologists in their local communities.
Conclusion
This study was conducted to understand the short-term
outcomes of patients who transferred care from pediatric
Table 3: Differences in insurance status pre and post-transfer.
Insurance Pre-Transfer
No. (%)
Post-Transfer
No. (%)
P value
Public 23 (74) 14 (45) 0.037
Private 8 (26) 17 (55)Pediatric Rheumatology 2009, 7:13 http://www.ped-rheum.com/content/7/1/13
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to adult rheumatology at our institution. We intend to use
these findings to inform the development of a formal
transition program that will prepare our patients for a suc-
cessful transition to adult care. Larger, prospective longi-
tudinal studies with longer follow-up will be necessary to
better understand the health care needs of adolescents
and young adults with chronic illness as they make the
critical transition from adolescence into adulthood.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
EVS and SP were responsible for study design. SP acquired
the data. EVS and AH performed the statistical analysis
and AH, EVS, DM, MC interpreted the data. AH, EVS, DM
and MC were responsible for the manuscript preparation.
All authors read and approved the final manuscript.
Acknowledgements
The authors would like to thank Su-Ellen Mortland, CNS, PNP for her con-
tribution to the preparation of this manuscript. This work was supported 
by the American College of Rheumatology Research and Education Foun-
dation's Physician Scientist Development Award to Dr. Hersh and NIH 
T32-AR-07304 to Dr. Curran.
References
1. Freed GL, Hudson EJ: Transitioning children with chronic dis-
eases to adult care: current knowledge, practices, and direc-
tions.  J Pediatr 2006, 148:824-827.
2. Wise PH: The future pediatrician: the challenge of chronic ill-
ness.  J Pediatr 2007, 151:S6-10.
3. Ravelli A, Martini A: Juvenile idiopathic arthritis.  Lancet 2007,
369:767-778.
4. Cassidy J, Petty R: Textbook of Pediatric Rheumatology Philadelphia: WB
Saunders; 2005. 
5. Fantini F, Gerloni V, Gattinara M, Cimaz R, Arnoldi C, Lupi E: Remis-
sion in juvenile chronic arthritis: a cohort study of 683 con-
secutive cases with a mean 10 year followup.  J Rheumatol 2003,
30:579-584.
6. Koivuniemi R, Leirisalo-Repo M: Juvenile chronic arthritis in
adult life: a study of long-term outcome in patients with juve-
nile chronic arthritis or adult rheumatoid arthritis.  Clin Rheu-
matol 1999, 18:220-226.
7. Zak M, Pedersen FK: Juvenile chronic arthritis into adulthood:
a long-term follow-up study.  Rheumatology (Oxford) 2000,
39:198-204.
8. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang
M:  Disease course and outcome of juvenile rheumatoid
arthritis in a multicenter cohort.  J Rheumatol 2002,
29:1989-1999.
9. Packham JC, Hall MA: Long-term follow-up of 246 adults with
juvenile idiopathic arthritis: social function, relationships and
sexual activity.  Rheumatology (Oxford) 2002, 41:1440-1443.
10. Packham JC, Hall MA: Long-term follow-up of 246 adults with
juvenile idiopathic arthritis: education and employment.
Rheumatology (Oxford) 2002, 41:1436-1439.
11. Urowitz MB, Feletar M, Bruce IN, Ibanez D, Gladman DD: Pro-
longed remission in systemic lupus erythematosus.  J Rheuma-
tol 2005, 32:1467-1472.
12. Moorthy LN, Robbins L, Harrison MJ, Peterson MG, Cox N, Onel KB,
Lehman TJ: Quality of life in paediatric lupus.  Lupus 2004,
13:234-240.
13. Ruperto N, Buratti S, Duarte-Salazar C, Pistorio A, Reiff A, Bernstein
B, Maldonado-Velazquez MR, Beristain-Manterola R, Maeno N, Takei
S, et al.: Health-related quality of life in juvenile-onset sys-
temic lupus erythematosus and its relationship to disease
activity and damage.  Arthritis Rheum 2004, 51:458-464.
14. Miettunen PM, Ortiz-Alvarez O, Petty RE, Cimaz R, Malleson PN,
Cabral DA, Ensworth S, Tucker LB: Gender and ethnic origin
have no effect on longterm outcome of childhood-onset sys-
temic lupus erythematosus.  J Rheumatol 2004, 31:1650-1654.
15. Tucker LB: Caring for the adolescent with systemic lupus ery-
thematosus.  Adolesc Med 1998, 9:59-67.
16. Scal P, Horvath K, Garwick A: Preparing for adulthood: health
care transition counseling for youth with arthritis.  Arthritis
Rheum 2009, 61:52-57.
17. Reid GJ, Irvine MJ, McCrindle BW, Sananes R, Ritvo PG, Siu SC, Webb
GD: Prevalence and correlates of successful transfer from
pediatric to adult health care among a cohort of young
adults with complex congenital heart defects.  Pediatrics 2004,
113:e197-205.
18. Callahan ST, Winitzer RF, Keenan P: Transition from pediatric to
adult-oriented health care: a challenge for patients with
chronic disease.  Curr Opin Pediatr 2001, 13:310-316.
19. Geenen SJ, Powers LE, Sells W: Understanding the role of health
care providers during the transition of adolescents with dis-
abilities and special health care needs.  J Adolesc Health 2003,
32:225-233.
20. Reiss JG, Gibson RW, Walker LR: Health care transition: youth,
family, and provider perspectives.  Pediatrics 2005, 115:112-120.
21. Robertson LP, McDonagh JE, Southwood TR, Shaw KL: Growing up
and moving on. A multicentre UK audit of the transfer of
adolescents with juvenile idiopathic arthritis from paediatric
to adult centred care.  Ann Rheum Dis 2006, 65:74-80.
22. McDonagh JE: Transition of care from paediatric to adult rheu-
matology.  Arch Dis Child 2007, 92:802-807.
23. Kipps S, Bahu T, Ong K, Ackland FM, Brown RS, Fox CT, Griffin NK,
Knight AH, Mann NP, Neil HA, et al.: Current methods of transfer
of young people with Type 1 diabetes to adult services.  Diabet
Med 2002, 19:649-654.
24. Vanelli M, Caronna S, Adinolfi B, Chiari G, Gugliotta M, Arsenio L:
Effectiveness of an uninterrupted procedure to transfer ado-
lescents with Type 1 diabetes from the Paediatric to the
Adult Clinic held in the same hospital: eight-year experience
with the Parma protocol.  Diabetes Nutr Metab 2004, 17:304-308.
25. Falcini F, Nacci F: Systemic lupus erythematosus in the young:
the importance of a transition clinic.  Lupus 2007, 16:613-617.
26. McDonagh JE, Shaw KL, Southwood TR: Growing up and moving
on in rheumatology: development and preliminary evalua-
tion of a transitional care programme for a multicentre
cohort of adolescents with juvenile idiopathic arthritis.  J Child
Health Care 2006, 10:22-42.
27. McDonagh JE, Southwood TR, Shaw KL: The impact of a coordi-
nated transitional care programme on adolescents with
juvenile idiopathic arthritis.  Rheumatology (Oxford) 2007,
46:161-168.
28. Rettig P, Athreya BH: Adolescents with chronic disease. Transi-
tion to adult health care.  Arthritis Care Res 1991, 4:174-180.
29. Tucker LB, Cabral DA: Transition of the adolescent patient
with rheumatic disease: issues to consider.  Rheum Dis Clin
North Am 2007, 33:661-672.
30. White PH: On the road to adulthood for youth with rheu-
matic diseases: what health care professionals can do.  Arthritis
Rheum 2008, 59:1054-1057.
31. Shaw KL, Southwood TR, McDonagh JE: Growing up and moving
on in rheumatology: a multicentre cohort of adolescents
with juvenile idiopathic arthritis.  Rheumatology (Oxford) 2005,
44:806-812.
32. Bell LE, Bartosh SM, Davis CL, Dobbels F, Al-Uzri A, Lotstein D, Reiss
J, Dharnidharka VR: Adolescent Transition to Adult Care in
Solid Organ Transplantation: a consensus conference
report.  Am J Transplant 2008, 8:2230-2242.
33. Lotstein DS, Inkelas M, Hays RD, Halfon N, Brook R: Access to care
for youth with special health care needs in the transition to
adulthood.  J Adolesc Health 2008, 43:23-29.
34. Dugueperoux I, Tamalet A, Sermet-Gaudelus I, Le Bourgeois M, Ger-
ardin M, Desmazes-Dufeu N, Hubert D: Clinical changes of
patients with cystic fibrosis during transition from pediatric
to adult care.  J Adolesc Health 2008, 43:459-465.